Preventium is 'where the prevention of breast and prostate cancer begins'March 17, 2009LAS VEGAS --Dr. Ercole Cavalieri and Dr. Eleanor Rogen of the University of Nebraska Medical Center, Eppley Institute for Research in Cancer, located in Omaha, Nebraska, have identified the triggering mechanism by which breast and prostate cancer cells begin. Preventium™ http://www.preventium.org is a recently developed dietary supplement that promises to reduce people's risk for breast and prostate cancer. Ercole Cavalieri, D.Sc. and research collaborator Eleanor Rogen, Ph.D. say: "We have found the first step that starts a cell down the road to becoming a cancer cell. By blocking this first step from happening, we feel we can stop the development of breast and prostate cancer." The researchers have discovered that certain estrogen derivates (metabolites) can react with deoxyribonucleic acid (DNA) to cause damage that may initiate the start of breast and prostate cancer. Estrogen can initiate cancer when natural protective mechanisms do not function properly in the body, which then allows estrogen metabolites to react with DNA. Since both men and women have naturally occurring estrogen, the triggering mechanism for breast and prostate cancer is identical. This research has been funded in part by nearly $40 million in direct funding from the National Cancer Institute and the U.S. Defense Department. Drs. Cavalieri and Rogan are the first cancer researchers to study the effects of Resveratrol on this process. New research establishes, that to be effective, additional compounds must be added for optimal effect. The combination of naturally occurring preventative agents Resveratrol, N-Acetyl-L-Cysteine (NAC), Lipoic Acid and Melatonin greatly enhances the body's natural protection mechanisms which, in turn, decrease the triggering mechanism involved in the formation of breast and prostate cancer cells. These compounds are available in a recently developed dietary supplement called Preventium™. Preventium, LLC |
|||||||||||||||||||||
| Related Prostate Cancer Current Events and Prostate Cancer News Articles Does prostate-specific antigen velocity help in early detection prostate cancer? The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection. New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. Chemo-radiation before prostate removal may prevent cancer recurrence Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. Blood vessels might predict prostate cancer behavior A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed? Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone. Task force develops new radiation guidelines for brachytherapy Radiation dose delivered to the prostate and nearby organs in every brachytherapy procedure should be carefully analyzed using post-implant CT or MRI and uniformly documented in every patient. 1 disease, not 1 demographic The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander." Cancer survivors may not be getting the help they need to stop smoking More than a quarter of cancer survivors who still smoke have not been advised to quit smoking by their health care providers in the last year, according to a study published by researchers at Fox Chase Cancer Center in the current issue of the Journal of General Internal Medicine. Experts issue call to reconsider screening for breast cancer and prostate cancer Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association." Detecting the undetectable in prostate cancer screening A team of Northwestern University researchers, using an extremely sensitive tool based on nanotechnology, has detected previously undetectable levels of prostate-specific antigen (PSA) in patients who have undergone radical prostatectomy. More Prostate Cancer Current Events and Prostate Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||